Will CLF and POSCO sign a definitive agreement for equity investment by September 30, 2026?

The MoU was signed September 2025, giving 7 months of due diligence by April 2026 with the deadline extended to September 30, 2026. The strategic rationale is strong: POSCO needs US production for Section 232 melt-and-pour compliance, and CLF is the only viable partner after US Steel was blocked. CLF has prioritized this deal above all else (delaying larger asset sales). However, timeline has already slipped from original H1 2026 target, due diligence is 'ongoing' as of March 2026, and the valuation gap ($700M for 10% implies $7B vs $4.1B market cap) creates negotiation friction. Korean corporate governance adds another layer of approval complexity.

Large cross-border equity deals typically take 9-18 months from MoU to definitive agreement. The MoU was September 2025, so September 2026 is at the 12-month mark — within typical range but tight. POSCO's due diligence on a company with $7.3B debt, $37M EBITDA, and a CEO who sold 50% of his stock may surface concerns. The Korean conglomerate governance process (POSCO board, POSCO Holdings, potentially Korean regulators) adds approval layers. CLF's declining stock price ($12.42 at MoU to $8.40 now) actually helps POSCO negotiate a lower valuation, which could accelerate OR delay (if CLF resists repricing). The resolution asks for 'definitive agreement' not 'closing' — which is the easier threshold.

The CEO's statement 'We are the only possibility for any company outside the border to be inside the border' reflects genuine strategic leverage, but also reveals negotiation posture that could create friction. POSCO's alternatives are limited (US Steel blocked, other mills don't have GOES), which favors deal completion. However, POSCO could decide to wait for better terms as CLF's financial position weakens. The hold on larger asset sales specifically for POSCO suggests CLF management considers this very likely to close — but that same hold creates pressure if it doesn't. Near coin-flip weighted slightly below 50% given timeline slip.

This deal has strong strategic logic for both sides and the 18-month window (MoU to Sep 30 deadline) is generous by M&A standards. POSCO needs a US production base badly enough to have signed an MoU, and the only realistic alternatives (greenfield EAF) would take 3-5 years and wouldn't produce GOES. The resolution threshold is definitive agreement, not regulatory approval or closing, which further favors YES. I'm modestly above 50% because the strategic imperative is strong enough to push through valuation disagreements.

Cross-border equity investments of this scale ($700M+) have a meaningful failure rate even after MoU. POSCO's due diligence team is now examining a company with 0.08x interest coverage, $37M EBITDA, a CEO who dumped half his stock, and a family CFO. These are red flags that institutional investors scrutinize heavily. Additionally, changes in Section 232 enforcement or exemptions could undermine the strategic rationale. Korean corporate approval processes are notoriously slow. I lean NO because the financial toxicity of CLF's balance sheet may give POSCO's risk committee pause despite the strategic logic.

Genuinely uncertain. The strategic logic favors completion, but the financial reality of CLF creates obstacles. The extended timeline (out to September 30) provides room, but the original H1 target was already missed as of April. In deal-making, slipped timelines are common and don't necessarily predict failure — but they do predict further delays. Even split on YES/NO with low confidence.

Strong strategic rationale but timeline already slipped. POSCO needs US production for Section 232 compliance and CLF is only viable partner. However, $7.3B debt and 0.08x coverage may concern POSCO's risk committee. September 30 deadline provides additional runway. Near coin-flip leaning slightly NO.

The MoU has been in place for 7 months and CLF has restructured its entire asset sale strategy around POSCO. Large strategic deals with this much commitment typically reach definitive agreement. POSCO's limited alternatives and Section 232 imperative push toward completion. Slight lean YES.

Cross-border deals face regulatory, governance, and valuation hurdles. Korean corporate process adds time. CLF's deteriorating financial position could either accelerate (POSCO gets better terms) or delay (POSCO concerned about solvency). Lean slightly NO on execution risk.